array(3) { ["company_details"]=> array(13) { ["name"]=> string(13) "Pharming B.V." ["slug"]=> string(20) "00474-nl-pharming-bv" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/6f06b060-b806-43f2-addd-a605083bf776" ["description"]=> string(987) "Pharming is a global biopharmaceutical company that develops and commercializes innovative protein replacement therapies and precision medicines for rare diseases. They are committed to being a sustainable partner for all stakeholder groups, including patients, healthcare professionals, employees, and shareholders. Pharming is headquartered in Leiden, the Netherlands, with its U.S. headquarters in Warren, New Jersey. They are listed on the Amsterdam Euronext and Nasdaq exchanges. Their vision is to become the leading global rare disease company and their mission is to bring solutions to unserved rare disease patients through drug development and commercialization. They aim to transform their pipeline to include multiple commercialized products in multiple geographies and to expand their technology portfolio. The company culture at Pharming emphasizes teamwork, self-development, and results orientation. They participate in investor conferences and provide financial updates." ["address_street"]=> string(12) "Darwinweg 24" ["address_place"]=> string(6) "Leiden" ["address_region"]=> NULL ["founding_date"]=> NULL ["website_domain"]=> string(12) "pharming.com" ["website_url"]=> string(24) "https://www.pharming.com" ["industry_codes"]=> array(1) { [0]=> string(75) "Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified" } ["employee_count"]=> NULL ["article_count"]=> int(54) } ["articles"]=> array(4) { [0]=> array(7) { ["title_en"]=> string(75) "Pharming Group to report third quarter 2023 financial results on October 26" ["snippet_en"]=> string(276) "Leiden, The Netherlands, October 12, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2023 financial results, for the period ended September 30, on Thursday, October 26, 2023." ["url"]=> string(81) "https://finance.yahoo.com/news/pharming-group-report-third-quarter-060000578.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/222fecfb-6b72-4556-9f3b-642d69c24b75" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2023-10-12" ["categories"]=> array(5) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(12) "Stock Market" [3]=> string(18) "Financial Distress" [4]=> string(9) "Investors" } } [1]=> array(7) { ["title_en"]=> string(52) "Attention to quarterly figures ING and SBM at Damrak" ["snippet_en"]=> string(303) "SBM Offshore saw turnover fall by almost a quarter in the first quarter. CEO Bruno Chabas nevertheless spoke of good performance and maintained expectations for the entire year. The company will also pay out 10 percent more dividend over 2022. Pharming also came up with figures. The biotechnologist saw" ["url"]=> string(84) "https://www.rd.nl/artikel/1019815-aandacht-voor-kwartaalcijfers-ing-en-sbm-op-damrak" ["image_url"]=> NULL ["source"]=> string(5) "rd.nl" ["publication_date"]=> string(10) "2023-05-11" ["categories"]=> array(3) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(12) "Stock Market" } } [2]=> array(7) { ["title_en"]=> string(70) "Pharming Group to report first quarter 2024 financial results on May 8" ["snippet_en"]=> string(304) "Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results, for the period ended March 31, on Wednesday, May 8, 2024. Pharming will host a presentation for" ["url"]=> string(142) "https://kommunikasjon.ntb.no/pressemelding/18070967/pharming-group-to-report-first-quarter-2024-financial-results-on-may-8?publisherId=4954260" ["image_url"]=> string(78) "https://images.businessradar.com/articles/901a2228-20e4-4ae4-824d-d26a8c659580" ["source"]=> string(6) "ntb.no" ["publication_date"]=> NULL ["categories"]=> array(2) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" } } [3]=> array(7) { ["title_en"]=> string(23) "Pharming records a loss" ["snippet_en"]=> string(239) "(ABM FN-Dow Jones) Pharming Group plunged into the red in the first quarter. This emerged from figures from the biotech company on Thursday. In the past quarter of 2023, Pharming reached an important milestone with the approval and long..." ["url"]=> string(69) "https://www.beursgorilla.nl/Nieuws/772880/Pharming-boekt-verlies.aspx" ["image_url"]=> string(78) "https://images.businessradar.com/articles/c8fc19ea-3461-4524-8660-9ad071e21e6e" ["source"]=> string(15) "beursgorilla.nl" ["publication_date"]=> NULL ["categories"]=> array(4) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(21) "Financial Performance" [3]=> string(12) "Stock Market" } } } ["category_annotations"]=> array(28) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(13) } [1]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(8) } [2]=> array(2) { ["name"]=> string(10) "Insolvency" ["count"]=> int(4) } [3]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(4) } [4]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(3) } [5]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(3) } [6]=> array(2) { ["name"]=> string(21) "Financial Performance" ["count"]=> int(2) } [7]=> array(2) { ["name"]=> string(9) "Investors" ["count"]=> int(2) } [8]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(2) } [9]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(2) } [10]=> array(2) { ["name"]=> string(10) "Executives" ["count"]=> int(1) } [11]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(1) } [12]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(1) } [13]=> array(2) { ["name"]=> string(24) "Government Interventions" ["count"]=> int(1) } [14]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(1) } [15]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(1) } [16]=> array(2) { ["name"]=> string(21) "Shareholders Feedback" ["count"]=> int(1) } [17]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(1) } [18]=> array(2) { ["name"]=> string(9) "Valuation" ["count"]=> int(1) } [19]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(1) } [20]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(1) } [21]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(1) } [22]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(1) } [23]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(1) } [24]=> array(2) { ["name"]=> string(5) "Debts" ["count"]=> int(1) } [25]=> array(2) { ["name"]=> string(19) "Economic Conditions" ["count"]=> int(1) } [26]=> array(2) { ["name"]=> string(7) "Economy" ["count"]=> int(1) } [27]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(1) } } } 00474-nl-pharming-bv